| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IVACC Stock Overview
Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care.
Intervacc AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr36.32 |
| 52 Week High | kr81.00 |
| 52 Week Low | kr28.68 |
| Beta | 1.42 |
| 1 Month Change | -9.43% |
| 3 Month Change | -8.05% |
| 1 Year Change | -53.97% |
| 3 Year Change | 182.65% |
| 5 Year Change | 329.82% |
| Change since IPO | 371.69% |
Recent News & Updates
We're Not Worried About Intervacc's (STO:IVACC) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Shareholder Returns
| IVACC | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -1.8% | 1.9% | 3.5% |
| 1Y | -54.0% | -21.1% | -20.7% |
Return vs Industry: IVACC underperformed the Swedish Biotechs industry which returned -21.1% over the past year.
Return vs Market: IVACC underperformed the Swedish Market which returned -20.7% over the past year.
Price Volatility
| IVACC volatility | |
|---|---|
| IVACC Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in SE Market | 12.5% |
| 10% least volatile stocks in SE Market | 4.5% |
Stable Share Price: IVACC is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: IVACC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 13 | Andreas Andersson | https://www.intervacc.se |
Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles.
Intervacc AB (publ) Fundamentals Summary
| IVACC fundamental statistics | |
|---|---|
| Market Cap | kr1.85b |
| Earnings (TTM) | -kr33.62m |
| Revenue (TTM) | kr8.91m |
205.8x
P/S Ratio-54.5x
P/E RatioIs IVACC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVACC income statement (TTM) | |
|---|---|
| Revenue | kr8.91m |
| Cost of Revenue | kr2.49m |
| Gross Profit | kr6.42m |
| Other Expenses | kr40.05m |
| Earnings | -kr33.62m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 31, 2022
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 72.08% |
| Net Profit Margin | -377.28% |
| Debt/Equity Ratio | 0.07% |
How did IVACC perform over the long term?
See historical performance and comparison